Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04044768 · ClinicalTrials.gov registry record · Phase 2

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

A Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma, sponsored by Uswm CT.

Active
Registry status
Phase 2
Development phase
52
Enrollment target
20
Study locations

NCT04044768 is a Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 52 participants, below the 152-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04044768, a Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma, is active but no longer recruiting, sponsored by Uswm CT.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
52 participants
Enrollment target
20
Study locations

Study Summary

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

Conditions Studied

Synovial Sarcoma Myxoid Liposarcoma

Interventions

  • GENETIC afamitresgene autoleucel (previously ADP-A2M4)

Study Locations (20)

California

  • City of Hope - Duarte
  • Stanford Cancer Center - Palo Alto

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Other

  • Centre Leon Berard - Lyon
  • Hospital Haut Leveque, CHU Bordeaux - Pessac

Colorado

  • University of Colorado - Aurora

Illinois

  • Northwestern University Robert H. Lurie Comprehensive Cancer Center - Chicago

Maryland

  • National Cancer Institute - Bethesda

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2019-08-13
Est. Completion 2038-04-01
Phase Phase 2

Sponsor

Uswm CT

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04044768

The ClinicalTrials.gov registry entry for NCT04044768 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (66% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Synovial Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which afamitresgene autoleucel (previously ADP-A2M4) is the first listed.

NCT04044768 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04044768 about?

NCT04044768 is a clinical study titled "Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma". This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

What is the current status of trial NCT04044768?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2019-08-13. Estimated completion is 2038-04-01.

What conditions does trial NCT04044768 study?

This clinical trial studies the following conditions: Synovial Sarcoma, Myxoid Liposarcoma.

What interventions are being tested in trial NCT04044768?

The interventions under investigation include: afamitresgene autoleucel (previously ADP-A2M4) (GENETIC).

Who is sponsoring clinical trial NCT04044768?

This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04044768 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Synovial Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Synovial Sarcoma

All registered trials for this condition

Myxoid Liposarcoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.